title: DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors.
abstract: A number of DNA minor groove-binding ligands (MGBLs) are known to exhibit antitumor and antimicrobial activities. We show that DNA topoisomerase (Topo) I may be a pharmacological target of MGBLs. In the presence of calf thymus Topo I, MGBLs induced limited but highly specific single-strand DNA breaks. The 3' ends of the broken DNA strands are covalently linked to Topo I polypeptides. Protein-linked DNA breaks are readily reversed by a brief heating to 65 degrees C or the addition of 0.5 M NaCl. These results suggest that MGBLs, like camptothecin, abort Topo I reactions by trapping reversible cleavable complexes. The sites of cleavage induced by MGBLs are distinctly different from those induced by camptothecin. Two of the major cleavage sites have been sequenced and shown to be highly A + T-rich, suggesting the possible involvement of a Topo I-drug-DNA ternary complex at the sites of cleavage. Different MGBLs also exhibit varying efficiency in inducing Topo I-cleavable complexes, and the order of efficiency is as follows: Hoechst 33342 and 33258 >> distamycin A > berenil > netropsin. The lack of correlation between DNA binding and cleavage efficiency suggest that, in addition to binding to the minor grooves of DNA, MGBLs must also interact with Topo I in trapping Topo I-cleavable complexes.
authors.affiliation: Department of Pharmacology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway 08854-5635.
authors.forename: A Y
authors.initials: AY
authors.lastname: Chen
authors.forename: C
authors.initials: C
authors.lastname: Yu
authors.forename: B
authors.initials: B
authors.lastname: Gatto
authors.forename: L F
authors.initials: LF
authors.lastname: Liu
mesh_terms: D000818:Animals; D001483:Base Sequence; D001562:Benzimidazoles / Q000737:chemistry / Q000378:metabolism; D006690:Bisbenzimidazole / Q000737:chemistry / Q000378:metabolism; D002417:Cattle; D004247:DNA / Q000737:chemistry* / Q000378:metabolism*; D004264:DNA Topoisomerases, Type I / Q000378:metabolism; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D004133:Diminazene / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism; D004214:Distamycins / Q000737:chemistry / Q000378:metabolism; D007211:Indoles / Q000737:chemistry / Q000378:metabolism; D007364:Intercalating Agents / Q000737:chemistry / Q000378:metabolism*; D007700:Kinetics; D008024:Ligands; D008969:Molecular Sequence Data; D009838:Oligodeoxyribonucleotides / Q000378:metabolism; D013329:Structure-Activity Relationship; D013950:Thymus Gland / Q000201:enzymology; D059004:Topoisomerase I Inhibitors
chemical_list: D001562:Benzimidazoles; D004214:Distamycins; D007211:Indoles; D007364:Intercalating Agents; D008024:Ligands; D009838:Oligodeoxyribonucleotides; D059004:Topoisomerase I Inhibitors; C007293:DAPI; C030000:stallimycin; D004247:DNA; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II; C003915:diminazene aceturate; D006690:Bisbenzimidazole; C017807:bisbenzimide ethoxide trihydrochloride; D004133:Diminazene